高龄与HIV感染者血浆及脑脊液中多替拉韦暴露升高相关
该回顾性治疗药物监测分析纳入207例每日一次多替拉韦且无相互作用的HIV感染者(457份血清)及41例脑脊液样本,发现年龄>50岁者脑脊液多替拉韦浓度及脑脊液/血浆比值显著更高,血清谷浓度随年龄增长呈线性回归显著关联。
要点
- 年龄>50岁者脑脊液多替拉韦浓度(13.8 vs 7.3 ng/mL)及脑脊液/血浆比值(0.57% vs 0.32%)显著更高。
- 线性回归显示年龄对多替拉韦血清谷浓度有显著影响(p=0.0013)。
- 脑脊液多替拉韦浓度与血浆浓度(ρ=0.374)及年龄(ρ=0.537)相关。
核心结论
- 高龄HIV感染者多替拉韦在血清和脑脊液中的暴露均升高。
研究设计与样本
- 回顾性治疗药物监测登记分析,纳入207例每日一次多替拉韦且无合并相互作用药物及显著临床状况的HIV感染者(457份血清样本)和41例接受多替拉韦的脑脊液样本患者。
主要发现
- 年龄>50岁者多替拉韦血清峰浓度[4230 ng/mL(2919-5272)vs 3830 ng/mL(2311-5057),p=0.311]及谷浓度[966 ng/mL(460-2085)vs 838 ng/mL(362-1587),p=0.056]呈非显著或边缘性升高。
- 脑脊液多替拉韦浓度与血浆浓度相关(ρ=0.374,p=0.016),与年龄相关(ρ=0.537,p=0.003)。
- 年龄>50岁者脑脊液多替拉韦浓度(13.8 vs 7.3 ng/mL,p=0.015)及脑脊液/血浆比值(0.57% vs 0.32%,p=0.017)更高。
临床怎么用
- 对高龄HIV感染者使用多替拉韦时,可关注血清及脑脊液暴露升高,必要时结合治疗药物监测评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People living with human immunodeficiency virus are ageing under combination antiretroviral treatments but data on drug exposure in serum and cerebrospinal fluid are limited. Dolutegravir is a widely used second-generation integrase strand transfer inhibitor: conflicting data suggest that neuropsychiatric side effects may present at a higher frequency in patients with higher dolutegravir serum concentrations. METHODS: We performed a retrospective analysis of our therapeutic drug monitoring registry identifying patients receiving once-daily dolutegravir without concomitant interacting drugs and significant clinical conditions. Data were analysed stratifying time after drug dose intake (maximum concentration 0.5-4 and trough concentration 21-27 h). Cerebrospinal fluid samples from patients enrolled in neurological studies and receiving dolutegravir were analysed for dolutegravir cerebrospinal fluid concentrations and cerebrospinal fluid-to-plasma ratios. Serum and cerebrospinal fluid concentrations were measured through validated chromatographic methods. RESULTS: We included 207 (providing 457 serum samples) and 41 patients (providing 41 cerebrospinal fluid samples). Participants were mostly male (68.2-72.8%) of median age of 50 years (50-53 years). Non-significant changes in dolutegravir maximum concentration and trough concentration were observed with age at Spearman's test (p values > 0.05); linear logistic regression showed a significant effect of age on dolutegravir trough concentration (p = 0.0013) (Fig. 1). Dolutegravir maximum concentration [3830 ng/mL (2311-5057) vs 4230 ng/mL (2919-5272), p = 0.311] and trough concentration [838 ng/mL (362-1587) vs 966 ng/mL (460-2085), p = 0.056] were non-significantly or borderline higher in patients aged > 50 years. Cerebrospinal dolutegravir concentrations were associated with plasma concentrations (ρ = 0.374, p = 0.016) and age (ρ = 0.537, p = 0.003); cerebrospinal fluid dolutegravir concentrations (13.8 vs 7.3 ng/mL, p = 0.015) and cerebrospinal fluid-to-plasma ratios (0.57 vs 0.32%, p = 0.017] were higher in participants aged > 50 years. CONCLUSIONS: We observed an increase in dolutegravir exposure in serum and in cerebrospinal fluid in older patients living with human immunodeficiency virus.
引用
- Calcagno A, Moltó J, Borghetti A, et al. Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. Clin Pharmacokinet. 2021. PMID: 32737820. doi:10.1007/s40262-020-00916-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。